Enzastaurin Versus Lomustine in Glioblastoma

Phase 3 Completed 397 enrolled Eli Lilly and Company

RandomizedParallel-groupOpen-labelTreatment

Summary

This protocol will test the activity of Enzastaurin vs. Lomustine in the treatment of recurrent brain cancer (specifically intracranial glioblastoma multiforme).

Timeline

Start: 2006-01
Primary completion: 2007-08
Completion: 2014-05

Publications

Results Wick W, Puduvalli VK, Chamberlain MC, van den Bent MJ, Carpentier AF, Cher LM, Mason W, Weller M, Hong S, Musib L, Liepa AM, Thornton DE, Fine HA. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010 Mar 1;28(7):1168-74. doi: 10.1200/JCO.2009.23.2595. Epub 2010 Feb 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Lomustine	Small molecule	100 mg/m2	Oral
Comparator	Lomustine	Small molecule	130 mg/m2	Oral
Subject	enzastaurin	Small molecule	500 mg	Oral

Enzastaurin Versus Lomustine in Glioblastoma

Summary

Timeline

Publications

Drugs

Indications